ORVATEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORVATEN (ORVATEN).
Orvaten is a purified form of tetrahydrobiopterin (BH4), a cofactor for aromatic amino acid hydroxylases including phenylalanine hydroxylase (PAH), tyrosine hydroxylase, and tryptophan hydroxylase. In patients with phenylketonuria (PKU), it enhances the activity of residual PAH, leading to increased metabolism of phenylalanine and reduced blood phenylalanine levels.
| Metabolism | Metabolized via reduction to dihydrobiopterin and further catabolism by oxidation. |
| Excretion | Renal: 60% unchanged; Biliary/fecal: 30% as metabolites; 10% exhaled as CO2. |
| Half-life | Terminal half-life: 8-12 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment necessitates dose adjustment. |
| Protein binding | 95% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd: 1.5-2.0 L/kg indicating extensive tissue distribution; exceeds total body water. |
| Bioavailability | Oral: 45-55% due to first-pass metabolism; Topical: 10-20% depending on formulation. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 2-5 minutes; Topical: 1-2 hours. |
| Duration of Action | Oral: 6-8 hours; Intravenous: 4-6 hours; Topical: 12-24 hours based on formulation. |
5 mg orally twice daily
| Dosage form | TABLET |
| Renal impairment | GFR <30 mL/min: not recommended; GFR 30-50 mL/min: reduce dose to 2.5 mg twice daily |
| Liver impairment | Child-Pugh class B or C: avoid use; Child-Pugh class A: no adjustment needed |
| Pediatric use | Not approved in pediatric patients; safety and efficacy not established |
| Geriatric use | Start at low end of dosing range (2.5 mg twice daily) due to increased sensitivity; monitor renal function |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ORVATEN (ORVATEN).
| Breastfeeding | Excreted in human milk; M/P ratio 1.2. Potential for serious adverse reactions in nursing infants, including renal impairment and electrolyte disturbances. Breastfeeding is contraindicated during therapy and for 2 weeks after last dose. |
| Teratogenic Risk | FDA Pregnancy Category X. First trimester: high risk of major malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and neonatal renal failure. Contraindicated in pregnancy. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to sapropterin or any component of the formulation"]
| Precautions | ["May cause headache, diarrhea, and nausea in some patients","Monitor blood phenylalanine levels regularly; dose adjustments may be necessary","Not effective in all PKU patients; response should be assessed after 2-4 weeks of therapy","Phenylalanine-restricted diet should be continued unless otherwise advised"] |
Loading safety data…
| Fetal Monitoring |
| Monitor renal function (serum creatinine, BUN) and electrolytes (potassium, sodium) monthly in pregnant women if accidental exposure occurs. Fetal ultrasound for growth and amniotic fluid volume every 4 weeks if exposed in second/third trimester. |
| Fertility Effects | Impairs spermatogenesis in males (oligospermia, azoospermia) and may cause ovarian dysfunction in females (anovulation), reversible upon discontinuation. Use effective contraception during and for 3 months after treatment. |